Meeting
2019 ASCO Annual Meeting
Association of baseline body mass index (BMI) with response and survival in patients (Pts) with advanced melanoma (MEL) receiving PD-1 inhibitors.
Authors
Amit Hemadri
UPMC Passavant Hospital, Pittsburgh, PA
Amit Hemadri , Huang Lin , Yan Lin , Amy Rose , Cindy Sander , Yana Najjar , Hassane M. Zarour , John M. Kirkwood , Diwakar Davar
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Biologic Correlates
Citation
J Clin Oncol 37, 2019 (suppl; abstr 9579)
DOI
10.1200/JCO.2019.37.15_suppl.9579
Abstract #
9579
Poster Bd #
150
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Association of medication (Med) and antibiotic (Abx) use with response and survival in advanced melanoma (MEL) receiving PD-1 inhibitors.
First Author: Amit Hemadri
Poster
2019 ASCO Annual Meeting
c-AMP/MAPK dysregulation and its impact on survival and response to immunotherapy in advanced melanomas.
First Author: Rami Al-Rohil
Poster
2016 ASCO Annual Meeting
Phase IB Study of pembrolizumab (Pembro) and pegylated-interferon alfa-2b (Peg-IFN) in advanced melanoma (MEL).
First Author: Diwakar Davar
Poster
2015 ASCO Annual Meeting
Safety profile of nivolumab (NIVO) in patients (pts) with advanced melanoma (MEL): A pooled analysis.
First Author: Jeffrey S. Weber